[Brazilian Consensus on second-generation antipsychotics and metabolic disorders].
OBJECTIVE
To discuss current aspects of use of antipsychotics considering their metabolic side effects profile, which includes weight gain, dyslipidemias, diabetes and metabolic syndrome. Such metabolic effects increase the risk of mortality by cardiovascular disease, which is the leading cause of death among schizophrenic patients.


METHODS
A consensus meeting was held, with participation of endocrinologists and psychiatrists specialists in schizophrenia and, based on a literature review, an article was elaborated emphasizing practical and helpful recommendations to clinicians.


CONCLUSIONS
Monitoring metabolic side effects is essential to patients taking antipsychotics, particularly in the case of second generation antipsychotics. Efficacy and tolerability should be carefully balanced in all phases of treatment.
Elkis
Helio
H
Instituto de Psiquiatria, Universidade de São Paulo, São Paulo, SP, Brasil. helkis@usp.br
Gama
Clarissa
C
Suplicy
Henrique
H
Tambascia
Marcos
M
Bressan
Rodrigo
R
Lyra
Ruy
R
Cavalcante
Saulo
S
Minicucci
Walter
W
D014150:Antipsychotic Agents / Q000009:adverse effects*; D001938:Brazil; D002318:Cardiovascular Diseases / Q000209:etiology / Q000401:mortality; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced / Q000150:complications; D050171:Dyslipidemias / Q000139:chemically induced; D006801:Humans; D008659:Metabolic Diseases / Q000139:chemically induced*; D024821:Metabolic Syndrome / Q000139:chemically induced / Q000150:complications; D009765:Obesity / Q000139:chemically induced; D012559:Schizophrenia / Q000188:drug therapy*
D014150:Antipsychotic Agents